Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Our products are used to help care for critically ill and chronically ill patients in hospitals, long-term care facilities, and at home.
Optimal nutritional support is critical for COVID-19 patients in the ICU, which is why experts recommend considering alternative lipid injectable emulsions (ILEs) for this patient population.1 As an early pioneer in alternative mixed lipid emulsions, Fresenius Kabi is expanding clinical nutrition options for critically ill patients.
A tireless dedication to driving advancements in lifesaving medicines and technologies has led to many firsts in the field, keeping Fresenius Kabi at the forefront of PN. We are proud to be the U.S. lipid injectable emulsion (ILE) market leader.2
Introduced the first lipid PN product for adults in more than 40 years
Pioneered the use of fish oil and omega-3s in PN products
Brought the benefits of alternative lipid emulsions to market
Developed the only pediatric lipid ILE product for PN-associated cholestasis (PNAC) in the U.S.
Developed the first and only three-chamber bag for adult PN in the U.S.
Are you hungry for fish oil facts or thirsting for knowledge on omega-3s in PN? Tune in to audio recordings featuring experts in the field.
Lipid source matters. Learn about Fresenius Kabi’s introduction of alternative oil sources in PN.
Launched the first three-chamber bag for adult PN
Introduced the first new lipid PN product for adults in 40 years
FDA approves first fish oil ILE for pediatric patients with PNAC
Pipeline products
References: 1. Martindale R, Patel J, Taylor B, et al. Nutrition therapy in critically ill patients with coronavirus disease 2019. JPEN J Parenter Enteral Nutr. 2020;44(7):1174-1184.
2. Data on File; 8/1/20; calculation includes: all ILEs approved in the US.
